Activation of the Zymogen to Urokinase-Type Plasminogen Activator Is Associated with Increased Interdomain Flexibility

被引:9
|
作者
Behrens, Manja A. [2 ,3 ]
Botkjaer, Kenneth A. [1 ,4 ]
Goswami, Sumit [5 ]
Oliveira, Cristiano L. P. [2 ,3 ]
Jensen, Jan K. [1 ,4 ]
Schar, Christine R. [1 ]
Declerck, Paul J. [5 ]
Peterson, Cynthia B. [6 ]
Andreasen, Peter A. [1 ,4 ]
Pedersen, Jan Skov [2 ,3 ]
机构
[1] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ, Dept Chem, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ, iNANO Interdisciplinary Nanosci Ctr, DK-8000 Aarhus C, Denmark
[4] Danish Chinese Ctr Proteases & Canc, Aarhus, Denmark
[5] Katholieke Univ Leuven, Dept Pharmaceut Sci, B-3000 Louvain, Belgium
[6] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA
基金
新加坡国家研究基金会;
关键词
small-angle X-ray scattering; serine protease; analytical ultracentrifugation; kringle; epidermal growth factor; PROTEIN UROKINASE; DOMAIN-STRUCTURE; STRUCTURAL BASIS; SCATTERING; SITE; MACROMOLECULES; INITIATION; RECEPTORS; MECHANISM; DYNAMICS;
D O I
10.1016/j.jmb.2011.05.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A key regulatory step for serine proteases of the trypsin clan is activation of the initially secreted zymogens, leading to an increase in activity by orders of magnitude. Zymogen activation occurs by cleavage of a single peptide bond near the N-terminus of the catalytic domain. Besides the catalytic domain, most serine proteases have N-terminal A-chains with independently folded domains. Little is known about how zymogen activation affects the interplay between domains. This question is investigated with urokinase-type plasminogen activator (uPA), which has an epidermal growth factor domain and a kringle domain, connected to the catalytic domain by a 15-residue linker. uPA has been implicated under several pathological conditions, and one possibility for pharmacological control is targeting the conversion of the zymogen pro-uPA to active uPA. Therefore, a small-angle X-ray scattering study of the conformations of pro-uPA and uPA in solution was performed. Structural models for the proteins were derived using available atomic-resolution structures for the various domains. Active uPA was found to be flexible with a random conformation of the amino-terminal fragment domain with respect to the serine protease domain. In contrast, pro-uPA was observed to be rigid, with the amino-terminal fragment domain in a fixed position with respect to the serine protease domain. Analytical ultracentrifugation analysis supported the observed difference between pro-uPA and uPA in overall shape and size seen with small-angle X-ray scattering. Upon association of either of two monoclonal Fab (fragment antigen-binding) fragments that are directed against the catalytic domain of, respectively, pro-uPA and uPA, rigid structures were formed. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:417 / 429
页数:13
相关论文
共 50 条
  • [31] Identification of a novel inhibitor of urokinase-type plasminogen activator
    Zhu, Ming
    Gokhale, Vijay M.
    Szabo, Lajos
    Munoz, Ruben M.
    Baek, Hyounggee
    Bashyam, Sridevi
    Hurley, Laurence H.
    Von Hoff, Daniel D.
    Han, Haiyong
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) : 1348 - 1356
  • [32] Properties of the urokinase-type plasminogen activator modified with phenylglyoxal
    Moukhametova, LI
    Aisina, RB
    Lomakina, GY
    Varfolomeev, SD
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2002, 28 (04) : 278 - 283
  • [33] THE CHICKEN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENE
    LESLIE, ND
    KESSLER, CA
    BELL, SM
    DEGEN, JL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1990, 265 (03) : 1339 - 1344
  • [34] Elucidating novel urokinase-type plasminogen activator inhibitors
    Smith, E.
    Spencer, J.
    Ali, M.
    Abdinejad, M.
    Kankanala, J.
    Fishwick, C.
    Philippou, H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (06) : E18 - E18
  • [35] A CELLULAR RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR
    BELIN, D
    BACCINO, D
    WOHLWEND, A
    ESTREICHER, A
    HUARTE, J
    VASSALLI, JD
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 46 - 46
  • [36] Elucidating novel urokinase-type plasminogen activator inhibitors
    Smith, E. L.
    John, S.
    Abdinejad, M.
    Kankanala, J.
    Fishwick, C. W. G.
    Philippou, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 819 - 819
  • [37] Urokinase-type plasminogen activator in carcinomatous pleural fluid
    Ishikawa, H
    Satoh, H
    Hasegawa, S
    Yazawa, T
    Naito, T
    Yamashita, YT
    Ohtsuka, M
    Ogata, T
    Kamma, H
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) : 1566 - 1571
  • [38] Urokinase-Type Plasminogen Activator Inhibits Efferocytosis of Neutrophils
    Yang, Yanping
    Friggeri, Arnaud
    Banerjee, Sami
    Bdeir, Khalil
    Cines, Douglas B.
    Liu, Gang
    Abraham, Edward
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (12) : 1516 - 1523
  • [39] Properties of the Urokinase-Type Plasminogen Activator Modified with Phenylglyoxal
    L. I. Moukhametova
    R. B. Aisina
    G. Yu. Lomakina
    S. D. Varfolomeev
    Russian Journal of Bioorganic Chemistry, 2002, 28 : 278 - 283
  • [40] Urokinase-type plasminogen activator in human gliomas in vitro
    Gillespie, J
    McCormick, D
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1996, 22 (05) : 454 - 454